Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis
- PMID: 30484857
- DOI: 10.1111/apt.15029
Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis
Abstract
Background: Vitamin D deficiency has been implicated in the outcome of chronic liver disease.
Aim: To determine the frequency of severe vitamin D deficiency in autoimmune hepatitis (AIH), assess its association with treatment non-response, and evaluate the relationship between vitamin D status and liver-related mortality and need for transplantation.
Methods: Two hundred and nine patients were evaluated by liver tissue examination at presentation. Serum vitamin D levels were determined, and serum levels <25 nmol/L (10 ng/mL) were considered severely deficient. Treatment non-response was defined as non-normalised aspartate aminotransferase/alanine aminotransferase and immunoglobulin G levels during conventional immunosuppressive therapy. Univariate and multivariate analyses were performed using binary logistic regression and Cox proportional hazards model.
Results: The mean vitamin D level was 60 ± 38 nmol/L (range, 3-263 nmol/L), and 42 patients (20%) had severe vitamin D deficiency. Treatment non-response was more common in patients with severe vitamin D deficiency than in patients without (59% vs 41%, P = 0.04). Severe vitamin D deficiency was also independently associated with a higher risk of developing cirrhosis (HR 3.40; 95% CI 1.30-8.87, P = 0.01) and liver-related mortality or requirement for liver transplantation (LT; HR 5.26, 95% CI, 1.54-18.0, P = 0.008). Patients with persistent severe deficiency following vitamin D supplementation continued to have poor outcomes.
Conclusions: Severe vitamin D deficiency is associated with treatment non-response, progression to cirrhosis, and liver-related death or need for LT. Severe vitamin D deficiency is a prognostic biomarker in AIH.
© 2018 John Wiley & Sons Ltd.
Comment in
-
Editorial: the role of vitamin D in autoimmune hepatitis.Aliment Pharmacol Ther. 2019 Feb;49(3):342-343. doi: 10.1111/apt.15075. Aliment Pharmacol Ther. 2019. PMID: 30663100 No abstract available.
-
Editorial: the role of vitamin D in autoimmune hepatitis-authors' reply.Aliment Pharmacol Ther. 2019 Feb;49(3):343-344. doi: 10.1111/apt.15091. Aliment Pharmacol Ther. 2019. PMID: 30663106 No abstract available.
-
Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander?Aliment Pharmacol Ther. 2019 Apr;49(7):958. doi: 10.1111/apt.15165. Aliment Pharmacol Ther. 2019. PMID: 30868627 No abstract available.
-
Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander? Authors' reply.Aliment Pharmacol Ther. 2019 Apr;49(7):959-960. doi: 10.1111/apt.15180. Aliment Pharmacol Ther. 2019. PMID: 30868634 No abstract available.
-
Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment-authors' reply.Aliment Pharmacol Ther. 2019 Apr;49(8):1104-1105. doi: 10.1111/apt.15154. Aliment Pharmacol Ther. 2019. PMID: 30920035 No abstract available.
-
Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment.Aliment Pharmacol Ther. 2019 Apr;49(8):1103. doi: 10.1111/apt.15147. Aliment Pharmacol Ther. 2019. PMID: 30920038 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical